Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention.

M a i n r e s u l t s Analysis was by intention to treat. The composite endpoint of any major coronary adverse outcome was lower in the homocysteine-lowering group than the placebo group, as was the need for repeated revascularization and repeated target lesion revascularization (Table). Adjustment for age, sex, and risk factors known to influence the need for repeated revascularization did not affect the results. The groups did not differ for nonfatal MI, cardiac death, or all-cause mortality.